Download Free Sample Report

The global Age-relatedMacularDegeneration (ARMD) Drugs market was valued at US$ 7949.4 million in 2022 and is projected to reach US$ 9754.6 million by 2029, at a CAGR of 3.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
 

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for ?straight-ahead? activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
This report aims to provide a comprehensive presentation of the global market for Age-relatedMacularDegeneration (ARMD) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age-relatedMacularDegeneration (ARMD) Drugs. This report contains market size and forecasts of Age-relatedMacularDegeneration (ARMD) Drugs in global, including the following market information:

• Global Age-relatedMacularDegeneration (ARMD) Drugs Market Revenue, 2018-2023, 2024-2032, ($ millions)
• Global top five companies in 2022 (%)

North America is the largest Age Related Macular Degeneration Drug market with about 65% market share. Europe is follower, accounting for about 29% market share.
The key players are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma etc. Top 3 companies occupied about 79% market share.
We surveyed the Age-relatedMacularDegeneration (ARMD) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Age-relatedMacularDegeneration (ARMD) Drugs Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Age-relatedMacularDegeneration (ARMD) Drugs Market Segment Percentages, by Type, 2022 (%)

• Anti VEGF Drugs
• Photosensitive Drugs
• Others

Global Age-relatedMacularDegeneration (ARMD) Drugs Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Age-relatedMacularDegeneration (ARMD) Drugs Market Segment Percentages, by Application, 2022 (%)

• Exudative ARMD
• Atrophy ARMD

Global Age-relatedMacularDegeneration (ARMD) Drugs Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Age-relatedMacularDegeneration (ARMD) Drugs Market Segment Percentages, By Region and Country, 2022 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Age-relatedMacularDegeneration (ARMD) Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
• Key companies Age-relatedMacularDegeneration (ARMD) Drugs revenues share in global market, 2022 (%)

Key players include:

• Roche
• Regeneron Pharmaceuticals
• Bayer
• Santen Oy
• Kanghong Pharmaceuticals
• Novartis
• Eli Lilly and Company
• TRACON Pharmaceuticals
• Pfizer
• GSK
• BIOCAD

Outline of Major Chapters:
Chapter 1: Introduces the definition of Age-relatedMacularDegeneration (ARMD) Drugs, market overview.
Chapter 2: Global Age-relatedMacularDegeneration (ARMD) Drugs market size in revenue.
Chapter 3: Detailed analysis of Age-relatedMacularDegeneration (ARMD) Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Age-relatedMacularDegeneration (ARMD) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.